United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 3 minute read Pharma Industry News Is Jagsonpal Pharmaceuticals’ asset-light model a blueprint for mid-cap pharma growth in India? Jagsonpal Pharmaceuticals’ asset-light model, zero-debt balance sheet, and 23% ROE show how mid-cap Indian pharma firms can grow without heavy capex. byPallavi MadhirajuJuly 29, 2025